Axsome Therapeutics
AXSM

$95.84

1.61%

Market Cap: $4.55B

About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees: 569

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 18 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

22% more funds holding in top 10

Funds holding in top 10: 9 [Q1] → 11 (+2) [Q2]

10% more call options, than puts

Call options by funds: $50M | Put options by funds: $45.3M

2.77% more ownership

Funds ownership: 82.96% [Q1] → 85.73% (+2.77%) [Q2]

5% more capital invested

Capital invested by funds: $3.13B [Q1] → $3.27B (+$142M) [Q2]

0% less funds holding

Funds holding: 253 [Q1] → 252 (-1) [Q2]

3% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 35

22% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 96

See Fund Rankings

Research analyst outlook

18 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$95

1%

downside

Avg. target

$128

33%

upside

High target

$180

88%

upside

18 analyst ratings

17 positive

94%

1 neutral

6%

0 negative

0%

Cantor Fitzgerald Charles Duncan 49% 1-year accuracy 39 / 79 met price target	12%upside $107	Overweight Reiterated	20 Sept 2024
Cantor Fitzgerald Charles Duncan 49% 1-year accuracy 39 / 79 met price target	12%upside $107	Overweight Reiterated	16 Sept 2024
Cantor Fitzgerald Charles Duncan 49% 1-year accuracy 39 / 79 met price target	12%upside $107	Overweight Reiterated	9 Sept 2024
Cantor Fitzgerald Charles Duncan 49% 1-year accuracy 39 / 79 met price target	12%upside $107	Overweight Reiterated	6 Sept 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 122 / 283 met price target	88%upside $180	Buy Reiterated	5 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about AXSM published over the past 30 days

Zacks Investment Research

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Zacks Investment Research

Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome's product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice.

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Zacks Investment Research

Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth

Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.

Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses.

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Zacks Investment Research

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

The Motley Fool

Why Axsome Therapeutics Stock Is Sinking Today

Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.

Why Axsome Therapeutics Stock Is Sinking Today

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

See News Rankings